Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1016/J.JNS.2014.02.017 | ||||
| Año | 2014 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
The Latin American MS Experts' Forum has developed practical recommendations on the initiation and optimization of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (RRMS). The recommendations reflect the unique epidemiology of MS and the clinical practice -environment in Latin American countries. Treatment response may be evaluated according to changes in relapses; progression, as assessed by the Expanded Disability Status Scale and the Timed 25-foot Walk; and lesion number on magnetic resonance imaging. Follow-up assessments are recommended every six months, or annually for stable patients. Cognitive function should be evaluated in all RRMS patients at baseline and annually thereafter. These recommendations are intended to assist clinicians in Latin America in developing a rational approach to treatment selection and sequencing for their RRMS patients. (C) 2014 Elsevier B.V. All rights reserved.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Correale, Jorge | Hombre |
Inst Neurol Res Dr Raul Carrea FLENI - Argentina
Fundacion Para La Lucha Contra Las Enfermedades Neurologicas de La Infancia - Argentina |
| 2 | Abad, Patricio | Hombre |
Hosp Metropolitano - Ecuador
Hospital Metropolitano - Ecuador |
| 3 | PAPAIS-ALVARENGA, REGINA MARIA | Mujer |
MS Hosp Da Lagoa - Brasil
Hospital da Lagoa - Brasil |
| 4 | Alves-Leon, Soniza Vieira | - |
UNIV FED RIO DE JANEIRO - Brasil
Universidade Federal do Rio de Janeiro - Brasil |
| 5 | Armas, Elizabeth | Mujer |
Hosp Univ Caracas - Venezuela
Hospital Universitario de Caracas - Venezuela |
| 6 | Barahona, J | - |
Clínica Alemana - Chile
|
| 7 | Buzo, Ricardo | Hombre |
Hosp Clin Montevideo - Uruguay
Hospital de Clínicas Dr. Manuel Quíntela - Uruguay |
| 8 | Corona, Teresa | Mujer |
Inst Nacl Neurol & Neurocirugia Manuel Velasco Su - México
Instituto Nacional de Neurología y Neurocirugía - México |
| 9 | Cristiano, Edgardo | Hombre |
Hosp Italian Buenos Aires - Argentina
Instituto Universitario del Hospital Italiano de Buenos Aires - Argentina |
| 10 | Gracia, Fernando | Hombre |
Fac Ciencias Salud ULACIT - Panamá
Facultad de Ciencias de la Salud-ULACIT - Panamá Laureate Education, Inc. - Estados Unidos |
| 11 | Bonitto, Juan Garcia | Hombre |
Serv Neurol Clin Marty & Entidad Prestado Serv Sa - Colombia
Clinica de Marly and Entidad Prestadora de Servicios de Salud Nogales - Colombia |
| 12 | Macias Islas, Miguel Angel | Hombre |
Dept Neurociencias CUCS UdeG - México
Departamento de Neurociencias CUCS UdeG - México |
| 13 | Soto, Arnoldo | Hombre |
Ctr Med Docente Trinidad - Venezuela
Centro Medico Docente La Trinidad - Venezuela |
| 14 | Vizcarra, Darwin | Hombre |
UNIV PERUANA CAYETANO HEREDIA - Perú
Universidad Peruana Cayetano Heredia - Perú |
| 15 | Freedman, Mark S. | Hombre |
Univ Ottawa - Canadá
Ottawa Hospital Research Institute - Canadá |
| Agradecimiento |
|---|
| The July 2013 meeting of the Latin American MS Experts' Forum was sponsored by Novartis Latin America. No funding was provided to the authors for writing the manuscript, and the sponsor did not contribute to the drafting, content or review of the manuscript. The authors acknowledge the assistance of Steven Manners of Communications Lansdowne, whose help was made possible through funding from Novartis Latin America and Novartis Canada Pharmaceuticals Inc. |
| The July 2013 meeting of the Latin American MS Experts' Forum was sponsored by Novartis Latin America. No funding was provided to the authors for writing the manuscript, and the sponsor did not contribute to the drafting, content or review of the manuscript. The authors acknowledge the assistance of Steven Manners of Communications Lansdowne, whose help was made possible through funding from Novartis Latin America and Novartis Canada Pharmaceuticals Inc . |